() An Illinois family is urging the Food and Drug Administration to restore access to Sarepta Therapeutics’ Elevidys, the only FDA-approved treatment for Duchenne’s muscular dystrophy.

Two of Alison and William Small’s three sons, Hunter and Noah, are diagnosed with Duchenne’s. Noah, 9, received the treatment in March. After three months of close monitoring and with no complications, the family said he’s made progress, including being able to swim and ride a bike.

But a recent FDA investigation has paused further distribution of Elevidys, following reports of at least three patient deaths, including an 8-year-old boy who died June 7 in Brazil.

The FDA said the deaths appear to have been a result of acute liver failure in those treated with Elevidys. However, Roche, which markets the drug outside the U.S. in partnership with Sarepta, confirmed the boy who died in Brazil was not enrolled in a clinical trial.

Sarepta temporarily halted distribution of Elevidys on July 22 to allow time to address FDA safety labeling updates and respond to regulatory inquiries.

‘We’re looking for clarity and transparency’: Father

The Smalls had been working through the insurance approval process for 10-year-old Hunter to receive the same treatment. That process is now on hold.

“(Noah’s) overall energy levels are so much higher, no complaining of leg pain and weakness like he typically would every evening,” Alison Small said. “We were so excited and thrilled to be able to give it to his older brother in the upcoming weeks, and this pause now is heartbreaking for us.”

Speaking to ‘s “Morning in America” on Monday, the Smalls called for transparency and a clear path forward from federal regulators. They said families affected by Duchenne’s deserve to understand the risks and that many believe the treatment is worth fighting for.

“Whether it’s through the administration or working with the FDA, what we’re looking for is some clarity and transparency … especially talking to the DMD community and families to understand where the risks are, why we believe this drug is worth fighting for and worth dosing to our son and the sons of other people in the community,” William Small said.

‘There is so much hope’: Alison Small

Allison Small said the family initially decided to move forward with the clinical trial despite being warned about the risks.

“We know the complications going in,” she said. “We had very serious conversations with our team of doctors, but we also know the natural progression of the disease. So we were willing to take that risk and have our sons dose with this drug.”

The family’s personal connection to Duchenne’s led them to establish the Small Heroes Foundation, which supports families affected by the disease. They’re now among a growing group of advocates calling on federal regulators to allow continued access to Elevidys for families who are willing to accept the risks.

“Anybody that’s starting this journey, there is so much hope, even with the pause of Elevidys, we’re really hopeful that this is going to get back on the market, and the opportunity for more boys to be treated will be out there,” Alison Small said.

Neither the FDA nor Sarepta has provided a timeline for when the pause may be lifted.

What is Duchenne’s muscular dystrophy?

Duchenne’s is a rare genetic condition that primarily affects boys, causing progressive muscle degeneration and premature death, according to the Muscular Dystrophy Association. It occurs in 1 in 3,500 to 5,000 male births.

Without treatment, most patients lose the ability to walk in their early teens and often do not survive into adulthood.

Elevidys is the only gene therapy approved by the FDA for the treatment of this disease.